IL242251B - Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations - Google Patents
Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutationsInfo
- Publication number
- IL242251B IL242251B IL242251A IL24225115A IL242251B IL 242251 B IL242251 B IL 242251B IL 242251 A IL242251 A IL 242251A IL 24225115 A IL24225115 A IL 24225115A IL 242251 B IL242251 B IL 242251B
- Authority
- IL
- Israel
- Prior art keywords
- methods
- autosomal dominant
- function mutations
- dominant hypercholesterolemia
- hypercholesterolemia associated
- Prior art date
Links
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 title 1
- 230000035772 mutation Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Mycology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361828730P | 2013-05-30 | 2013-05-30 | |
| US201361889553P | 2013-10-11 | 2013-10-11 | |
| US201361901212P | 2013-11-07 | 2013-11-07 | |
| PCT/US2014/040050 WO2014194111A1 (en) | 2013-05-30 | 2014-05-29 | Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL242251B true IL242251B (en) | 2020-02-27 |
Family
ID=51205567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL242251A IL242251B (en) | 2013-05-30 | 2015-10-25 | Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20140356370A1 (OSRAM) |
| EP (1) | EP3004172B1 (OSRAM) |
| JP (1) | JP6423868B2 (OSRAM) |
| KR (1) | KR20160013046A (OSRAM) |
| CN (2) | CN105263963B (OSRAM) |
| AU (1) | AU2014274077B2 (OSRAM) |
| CA (1) | CA2912101A1 (OSRAM) |
| EA (1) | EA201592304A1 (OSRAM) |
| IL (1) | IL242251B (OSRAM) |
| TW (1) | TWI682780B (OSRAM) |
| WO (1) | WO2014194111A1 (OSRAM) |
| ZA (1) | ZA201507798B (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| MX347602B (es) | 2011-01-28 | 2017-05-03 | Sanofi Biotechnology | Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9. |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| PL4252857T3 (pl) | 2011-09-16 | 2025-03-03 | Regeneron Pharmaceuticals, Inc. | Sposoby redukowania poziomów lipoproteiny(a) poprzez podawanie inhibitora proproteinowej konwertazy subtylizyny keksyny-9 (pcsk9) |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| CA2914721A1 (en) | 2013-06-07 | 2014-12-11 | Regeneron Pharmaceuticals, Inc. | Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9 |
| PL3055333T4 (pl) * | 2013-10-11 | 2020-07-27 | Sanofi Biotechnology | Wykorzystanie inhibitora pcsk9 do leczenia hyperlipidemii |
| JP6616298B2 (ja) | 2013-11-12 | 2019-12-04 | サノフィ・バイオテクノロジー | Ｐｃｓｋ９阻害剤と共に使用するための投薬レジメン |
| US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
| CA2955294A1 (en) | 2014-07-16 | 2016-01-21 | Sanofi Biotechnology | Methods for treating patients with heterozygous familial hypercholesterolemia (hefh) |
| TW201628649A (zh) | 2014-10-09 | 2016-08-16 | 再生元醫藥公司 | 減少醫藥調配物中微可見顆粒之方法 |
| WO2016100615A2 (en) * | 2014-12-18 | 2016-06-23 | The University Of Chicago | Methods and composition for neutralization of influenza |
| US10772956B2 (en) | 2015-08-18 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| SG11201900201YA (en) | 2016-08-16 | 2019-02-27 | Regeneron Pharma | Methods for quantitating individual antibodies from a mixture |
| AU2017350807B2 (en) | 2016-10-25 | 2022-07-07 | Regeneron Pharmaceuticals, Inc. | Methods and systems for chromatography data analysis |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| CA3058567A1 (en) | 2017-04-13 | 2018-10-18 | Cadila Healthcare Limited | Novel peptide based pcsk9 vaccine |
| AU2018291702A1 (en) * | 2017-06-30 | 2020-02-06 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition comprising PCSK-9 antibody and use thereof |
| CN118416215A (zh) | 2017-09-19 | 2024-08-02 | 里珍纳龙药品有限公司 | 减少粒子形成的方法以及由其形成的组合物 |
| IL296138B2 (en) | 2017-12-13 | 2024-11-01 | Regeneron Pharma | Devices and systems for chromatography column bed support management and related methods |
| TWI853823B (zh) | 2018-07-02 | 2024-09-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| CR20210441A (es) | 2019-01-18 | 2022-03-11 | Astrazeneca Ab | Inhibidores de la pcsk9 y métodos de uso de los mismos |
| AU2020388182A1 (en) * | 2019-11-18 | 2022-06-02 | Ad Pharmaceuticals Co., Ltd. | Anti-PCSK9 antibody and use thereof |
| EP4072672A1 (en) * | 2019-12-10 | 2022-10-19 | Regeneron Pharmaceuticals, Inc. | Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia |
| IL300439A (en) | 2020-08-25 | 2023-04-01 | Regeneron Pharma | Treatment of sepsis with PCSK9 and LDLR modulators |
| CN116189765B (zh) * | 2023-02-23 | 2023-08-15 | 上海捷易生物科技有限公司 | 一种iPS细胞遗传学风险评估系统及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP1471152A1 (en) * | 2003-04-25 | 2004-10-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mutations in the human PCSK9 gene associated to hypercholesterolemia |
| US8357371B2 (en) | 2008-12-15 | 2013-01-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to PCSK9 |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| AR079336A1 (es) * | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
| AR088782A1 (es) * | 2011-04-29 | 2014-07-10 | Sanofi Sa | Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| PL4252857T3 (pl) * | 2011-09-16 | 2025-03-03 | Regeneron Pharmaceuticals, Inc. | Sposoby redukowania poziomów lipoproteiny(a) poprzez podawanie inhibitora proproteinowej konwertazy subtylizyny keksyny-9 (pcsk9) |
-
2014
- 2014-05-28 TW TW103118526A patent/TWI682780B/zh not_active IP Right Cessation
- 2014-05-29 WO PCT/US2014/040050 patent/WO2014194111A1/en not_active Ceased
- 2014-05-29 KR KR1020157033966A patent/KR20160013046A/ko not_active Ceased
- 2014-05-29 US US14/290,462 patent/US20140356370A1/en not_active Abandoned
- 2014-05-29 AU AU2014274077A patent/AU2014274077B2/en not_active Ceased
- 2014-05-29 EP EP14739600.6A patent/EP3004172B1/en active Active
- 2014-05-29 CN CN201480031344.7A patent/CN105263963B/zh active Active
- 2014-05-29 EA EA201592304A patent/EA201592304A1/ru unknown
- 2014-05-29 CA CA2912101A patent/CA2912101A1/en not_active Abandoned
- 2014-05-29 JP JP2016516825A patent/JP6423868B2/ja active Active
- 2014-05-29 CN CN202110182897.4A patent/CN113144195A/zh active Pending
-
2015
- 2015-10-19 ZA ZA2015/07798A patent/ZA201507798B/en unknown
- 2015-10-25 IL IL242251A patent/IL242251B/en not_active IP Right Cessation
-
2019
- 2019-03-28 US US16/367,795 patent/US20190330371A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN105263963A (zh) | 2016-01-20 |
| ZA201507798B (en) | 2017-04-26 |
| EP3004172B1 (en) | 2019-11-27 |
| CA2912101A1 (en) | 2014-12-04 |
| US20140356370A1 (en) | 2014-12-04 |
| EP3004172A1 (en) | 2016-04-13 |
| EA201592304A1 (ru) | 2016-04-29 |
| AU2014274077B2 (en) | 2019-09-26 |
| CN105263963B (zh) | 2021-03-05 |
| US20190330371A1 (en) | 2019-10-31 |
| KR20160013046A (ko) | 2016-02-03 |
| HK1216896A1 (en) | 2016-12-09 |
| JP2016522211A (ja) | 2016-07-28 |
| JP6423868B2 (ja) | 2018-11-14 |
| TW201536315A (zh) | 2015-10-01 |
| AU2014274077A1 (en) | 2015-11-19 |
| TWI682780B (zh) | 2020-01-21 |
| WO2014194111A1 (en) | 2014-12-04 |
| CN113144195A (zh) | 2021-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL242251B (en) | Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations | |
| IL278018A (en) | Methods for the treatment or prevention of ophthalmological conditions | |
| IL244014A0 (en) | Combined therapy for the treatment of glioblastoma | |
| SI3057993T1 (sl) | Postopki za zdravljenje bolezenskih stanj, povezanih z aktivacijo komplementov, odvisnih od MASP-2 | |
| PL3169353T3 (pl) | SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH) | |
| AU350549S (en) | Breathalyzer | |
| IL245704B (en) | ccr6 compounds | |
| EP2964671A4 (en) | METHODS OF TREATING ACUTE RENAL FAILURE | |
| GB201312318D0 (en) | Novel methods and compounds | |
| IL246541B (en) | From a treatment system - guided eyepiece - versatile light | |
| GB201304872D0 (en) | Treatment | |
| HUE048625T2 (hu) | Módszer rák kezelésére | |
| IL244871A0 (en) | Laser treatment device | |
| GB201309375D0 (en) | Medical methods and compounds for medical use | |
| GB201311984D0 (en) | Methods and compounds for preventing or treating osteoarthritis | |
| GB201307310D0 (en) | Treatment | |
| GB201301975D0 (en) | New method for the purpose of safening | |
| GB201309376D0 (en) | Medical methods and compounds for medical use | |
| PT2764941T (pt) | Tesoura-prensa de resíduos | |
| IL250080A0 (en) | Treatment methods for patients with familial heterozygous hypercholesterolemia | |
| GB2513175B (en) | Methods and apparatus for reselection | |
| GB201322764D0 (en) | Treating places | |
| GB201307546D0 (en) | Laser treatment | |
| TH1501000891B (th) | เครื่องชง และวิธีการสำหรับดำเนินการเครื่องชง | |
| GB201321115D0 (en) | Treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| MM9K | Patent not in force due to non-payment of renewal fees |